patently clear facts re gtg !!!

Over the past week, there have been several posts and comments made by a HC member that are completely FALSE and MISLEADING re GTG and its patents..and future potential!

Perhaps its because GTG has clearly gained some momentum in recent months/weeks not only on the ASX and NASDAQ, but also in the commercial and media arenas....

Perhaps its simply because some people have been burnt and are intent on 'seeking revenge' against GTG and/or its shareholders. (Strangely, we never did get any clarity on that issue from the same member after Ganda asked again).

As a result, here are some absolute FACTS that will negate the need for any further debate (or misinformation) on the subject. (I should state that the following is public information and readily available, if you want or need to check).

The 'JUNK DNA' patents that were referred to can basically be split into 2 groups - ANALYSIS & MAPPING.

FACT - The 'analysis' patent has expired, but even an expired patent has significant value, as evidenced by the increasing number of licenses and amounts being generated.

This is because even an expired patent allows GTG to seek payment or compensation etc against any company who has infringed in the past. It is also worth noting that different countries have different time periods for GTG to claim (up to 6 years or more) prior to the patent expiring This in itself creates enormous potential income for GTG and could still generate in excess of $50M globally, even though this patent has expired.

It should be noted that GTG has in NO way failed to disclose or advise the markets re any patent expiry. Patent details are public information and available for anyone to find, if they wish.

FACT - The 'mapping' patent has NOT expired and won't expire until 2015, and then the same will apply as listed above, so the potential $$ is again enormous.

FACT - Merv WAS and still IS the driving force behind the licensing program. He is the "President of IP and Global Licensing" for GTG, and any licenses being announced are no doubt the results of his efforts (obviously there are assistants and legal teams as well).

As previously stated, there are still many many other opportunities that could 'strike gold' and with the Brevagen release just around the corner, I expect that GTG (and we as shareholders) have only scratched the surface of what is still to come.

As evidenced by recent media reports, increased volumes and a surging share price, the rest of the world
would seem to agree, and are certainly taking note of the enormous global potential GTG has secured, and will no doubt prove in the months and years to come.